Key result
The wearable cardioverter-defibrillator has evolved beyond shock delivery to serve as a multiparameter monitoring device for detecting imminent heart failure decompensation.
Why the study?
There is a growing need for telemedical concepts in the detection and treatment of heart failure and its arrhythmias.
The wearable cardioverter-defibrillator is evolving beyond sudden cardiac death prevention to include multiparameter monitoring for early detection of heart failure decompensation.
May enable earlier HF intervention via WCD monitoring; leaves open prospective validation before practice change.
A wearable cardioverter-defibrillator (WCD) is a temporary treatment option for patients at high risk for sudden cardiac death (SCD) and for patients who are temporarily not candidates for an implantable cardioverter defibrillator (ICD). In addition, the need for telemedical concepts in the detection and treatment of heart failure (HF) and its arrhythmias is growing. The WCD has evolved from a shock device detecting malignant ventricular arrhythmias (VA) and treating them with shocks to a heart-failure-monitoring device that captures physical activity and cardioacoustic biomarkers as surrogate parameters for HF to help the treating physician surveil and guide the HF therapy of each individual patient. In addition to its important role in preventing SCD, the WCD could become an important tool in heart failure treatment by helping prevent HF events by detecting imminent decompensation via remote monitoring and monitoring therapy success.
No takes yet. Share an insight, caveat, or question.
Rohrer et al. (2021) conducted a review in Sudden cardiac death and heart failure. Wearable cardioverter-defibrillator (WCD) was evaluated. The wearable cardioverter-defibrillator has evolved beyond shock delivery to serve as a multiparameter monitoring device for detecting imminent heart failure decompensation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: